01:52 , Feb 8, 2019 |  BC Week In Review  |  Company News

BioMotiv, Rutgers launch TamRx

Cancer immunotherapy company TamRx LLC (Cleveland, Ohio) launched Feb. 7 from pharmaceutical accelerator BioMotiv LLC (Cleveland, Ohio), shooting to reach the clinic with its pan-TAM inhibitors in 2021. The company is based on research from...
23:45 , Feb 7, 2019 |  BC Extra  |  Company News

BioMotiv, Rutgers launch TamRx

Cancer immunotherapy company TamRx LLC (Cleveland, Ohio) launched Thursday from pharmaceutical accelerator BioMotiv LLC (Cleveland, Ohio), shooting to reach the clinic with its pan-TAM inhibitors in 2021. The company is based on research from Rutgers...
17:47 , May 11, 2018 |  BC Week In Review  |  Clinical News

Mirati reports updated Phase II data for sitravatinib, Opdivo combo

Mirati Therapeutics Inc. (NASDAQ:MRTX) reported data from 23 evaluable non-small cell lung cancer (NSCLC) patients who experienced disease progression following prior treatment with a checkpoint inhibitor in a Phase II trial showing that once-daily oral...
16:03 , Jan 15, 2018 |  BC Extra  |  Preclinical News

Combination therapy could treat tumors resistant to MAPK pathway inhibitors

In a study published in Nature Medicine , Genmab A/S (CSE:GEN; Pink:GMXAY) and academic researchers identified a combination therapy approach that could combat drug resistance in heterogeneous tumors. Melanoma tumors with BRAF mutations that are...
01:20 , Jan 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Retinitis Rat studies suggest transplants of human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) sheets could help treat retinitis pigmentosa. The sheets were generated by culturing hESC-derived RPEs on a human amniotic membrane...
00:53 , Dec 21, 2017 |  BC Extra  |  Preclinical News

Researchers develop hESC-derived RPE cell sheet

In a paper published in Science Translational Medicine , researchers from Institut National de la Santé et de la Recherche Médicale (INSERM) and colleagues developed a technique to grow human stem cell-derived retinal pigment epithelial...
20:18 , Sep 22, 2017 |  BC Week In Review  |  Clinical News

Mirati reports partial responses in Phase II NSCLC trial of sitravatinib

Mirati Therapeutics Inc. (NASDAQ:MRTX) reported preliminary data from a Phase II trial showing that sitravatinib (MGCD516) in combination with PD-1 mAb Opdivo nivolumab led to 3 confirmed partial responses in 11 evaluable patients with non-squamous...
21:25 , Sep 15, 2017 |  BC Extra  |  Clinical News

Mirati, Loxo gain on RET inhibitor presentations

Mirati Therapeutics Inc. (NASDAQ:MRTX) jumped $6.45 (136%) to $11.20 on Friday after reporting Phase II data for its Ret proto-oncogene (RET) inhibitor sitravatinib (MGCD516), making it the second company this week to see its stock...
01:03 , Jan 28, 2017 |  BioCentury  |  Strategy

MER-made

Dong-A ST Co. Ltd. has spent the last four years building an R&D organization and using its chemistry chops to begin developing first-in-class drug candidates against genetically validated targets. A December cancer immunotherapy deal with...
23:15 , Dec 30, 2016 |  BC Extra  |  Company News

Dong-A grants AbbVie rights to MERTK inhibitor

Dong-A ST Co. Ltd. (KSE:170900) granted AbbVie Inc. (NYSE:ABBV) exclusive rights outside South Korea to a c-Mer proto-oncogene tyrosine kinase (MERTK) inhibitor that is in preclinical development to treat cancer. The Korean biotech deferred questions...